The prospect of targeting SORT1 opens avenues for novel therapeutic strategies addressing not only heart-related disorders but also neurodegenerative diseases, where protein misfolding and aggregation are prevalent, as well as various cancers, where dysregulated signalling pathways contribute to tumorigenesis. Here, SORT1 is linked to cancer.